Jefferies increased Amgen's price target from $367 to $410 following positive Phase 3 trial results for dazodalibep, a drug targeting systemic Sjögren's disease. The drug showed significant improvement in disease activity as early as week four and may have better safety compared to competitors. Jefferies raised peak sales estimates for dazodalibep to $4.5 billion and sees Sjögren's as a key growth area for Amgen beyond its cardiometabolic pipeline. Further data from a second Phase 3 trial on symptomatic Sjögren's is expected in late 2026.
As of September 24, 2026, Amgen (AMGN) trades at USD 408.92 on Pluang, close to its 52-week high of USD 444.12 but well above its 52-week low of USD 271.18. Despite the recent positive news, the stock shows a slight 1-day decline of 0.32% and a majority of Pluang users are selling, with 85% of order activity on the platform being sell orders. The dividend yield stands at 2.46%, and the typical hold time on Pluang is 71 days, indicating moderate investor engagement.
Amgen's stock price target was raised to $410 following positive results from its experimental drug dazodalibep in a late-stage trial for Sjögren's disease. The drug showed significant improvement in patients' symptoms, with effects seen as early as ...
Amgen and Merck both pay quarterly dividends and raise them annually, but Amgen offers a higher yield (2.6% vs. 2.29%) and has consistently raised dividends by about 6% annually. While Merck relies heavily on its Keytruda franchise, facing a looming ...
